Hydromorphone (Dilaudid) - Prices & Where to Buy

What Is Hydromorphone?

Hydromorphone is the generic name for Dilaudid, a potent opioid analgesic belonging to the opioid agonist class of medications. Opioid agonists work by binding to specific receptors in the brain and spinal cord to reduce the perception of pain.

Hydromorphone is approximately 4 to 8 times more potent than morphine on a milligram basis, making it one of the more powerful opioid analgesics available. It was first approved by the FDA and has been used for decades in the management of severe pain.

Hydromorphone is designated as a Schedule II controlled substance under the federal Controlled Substances Act, indicating a high potential for abuse that may lead to severe psychological or physical dependence.

How Hydromorphone Works

Hydromorphone works by binding to mu-opioid receptors in the central nervous system (CNS). These receptors are distributed throughout the brain, spinal cord, and peripheral tissues, and play a key role in pain modulation.

When hydromorphone binds to mu-opioid receptors, it activates them, producing analgesia (pain relief), euphoria, sedation, and respiratory depression. The activation of these receptors inhibits the ascending pain pathways in the spinal cord and alters the perception of and emotional response to pain in the brain.

Due to its high lipophilicity and potency at the mu receptor, hydromorphone has a rapid onset of action, particularly when administered intravenously. The half-life of hydromorphone is approximately 2 to 3 hours, with effects typically lasting 3 to 4 hours for immediate-release formulations.

FDA Schedule & Classification

FDA-Approved Uses

Hydromorphone is FDA-approved for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.

• Acute severe pain: Post-surgical pain, trauma-related pain, and pain associated with medical procedures
• Cancer pain: Often used for breakthrough cancer pain in patients already on opioid therapy
• Hospital-based pain management: Injectable formulations are commonly used in emergency departments and inpatient settings
• Palliative care: Used for pain management in end-of-life care situations

Due to its high potency and significant abuse potential, hydromorphone is generally reserved for situations where weaker opioids are insufficient. It is intended for short-term use when possible; long-term use requires careful risk-benefit assessment.

Dosage Forms & Strengths

Immediate-Release Oral Tablets

The usual starting dose for opioid-naive adults is 2 mg to 4 mg taken orally every 3 to 4 hours as needed for pain. The dose should be titrated based on the patient's analgesic response and side effect profile.

Injectable Formulations

Injectable hydromorphone has a rapid onset (5—15 minutes for IV), making it useful for acute pain management. Elderly patients and those with hepatic or renal impairment may require lower starting doses with slower titration.

Side Effects

Common Side Effects

These are the most frequently reported side effects of hydromorphone:

• Constipation — the most common side effect; may require laxative use
• Nausea and vomiting — especially when initiating therapy
• Dizziness — avoid standing quickly
• Sedation and drowsiness — avoid driving or operating machinery
• Headache
• Dry mouth
• Excessive sweating (diaphoresis)
• Pruritus (itching)
• Flushed skin

Serious Side Effects

Contact your healthcare provider or seek emergency medical attention if you experience:

• Respiratory depression — slow, shallow, or difficulty breathing; can be life-threatening and is the primary cause of opioid-related death
• Severe allergic reaction (anaphylaxis) — hives, difficulty breathing, swelling of face/throat
• Severe hypotension — dangerously low blood pressure
• Adrenal insufficiency — fatigue, nausea, low blood pressure
• Serotonin syndrome — agitation, hallucinations, rapid heart rate, fever (when combined with serotonergic drugs)
• QT prolongation — irregular heartbeat

Drug Interactions

Hydromorphone interacts with numerous medications. The most significant interactions involve other CNS depressants.

Major Interactions (Avoid or Use Extreme Caution)

• Other opioids — concurrent use increases risk of respiratory depression and death
• Benzodiazepines (alprazolam, diazepam, lorazepam) — profound sedation and respiratory depression; FDA black box warning
• Alcohol — significantly increases sedation and respiratory depression risk
• MAO inhibitors — can cause unpredictable and potentially fatal interactions; avoid concomitant use
• Serotonergic drugs (SSRIs, SNRIs, triptans) — risk of serotonin syndrome

Moderate Interactions (Monitor Closely)

• Anticholinergic drugs — additive constipation and urinary retention
• CYP3A4 inhibitors (ketoconazole, erythromycin) — may increase hydromorphone levels
• Mixed agonist-antagonist opioids (buprenorphine, nalbuphine) — may reduce analgesic effect and precipitate withdrawal

Dependence and Withdrawal

Hydromorphone carries a significant risk of physical and psychological dependence. Withdrawal symptoms may include anxiety, restlessness, muscle aches, diarrhea, nausea, vomiting, insomnia, and piloerection (goosebumps). Withdrawal should be managed by gradual dose tapering under medical supervision.

Precautions & Warnings

• Pregnancy: Use during pregnancy may cause neonatal opioid withdrawal syndrome (NOWS) in newborns. Prolonged use during pregnancy can result in life-threatening withdrawal symptoms in the neonate.
• Breastfeeding: Hydromorphone is excreted in breast milk. Opioids can cause serious adverse effects in breastfed infants including drowsiness, breathing difficulties, and death. Breastfeeding is generally not recommended.
• Elderly patients: Increased sensitivity to opioids. Start at lower doses and titrate slowly. Higher risk of respiratory depression, falls, and fractures.
• Liver disease: Hydromorphone is metabolized by the liver. Patients with hepatic impairment require dose reduction.
• Kidney disease: Renal impairment can lead to accumulation of active metabolites. Use with caution.
• Respiratory conditions: Use extreme caution in patients with COPD, asthma, sleep apnea, or other respiratory conditions — opioids can suppress respiratory drive.
• History of substance use disorder: Increased risk of misuse. Use with caution and close monitoring. Consider prescription drug monitoring programs (PDMP).
• Intrathecal use: Do NOT administer intrathecally (into the spinal canal) — the preservative in some formulations can cause neurotoxicity.
• Driving and machinery: Do not drive or operate heavy machinery until you know how this medication affects you.
• Opioid Overdose Risk: Have naloxone (Narcan) available. Educate family members on recognizing signs of overdose.

When to Contact a Clinician

Reach out to your healthcare provider if you experience any of the following:

• Pain is not improving or is worsening after starting the medication
• You notice new or unexpected side effects
• You feel you need to take more medication to achieve the same effect (tolerance)
• You are having difficulty functioning at work or home due to sedation
• You are experiencing mood changes, depression, or thoughts of self-harm
• You are pregnant or planning to become pregnant
• You have questions about how long you should take this medication
• You want to stop the medication — never stop abruptly without medical guidance

Seek emergency care immediately if you experience seizures, difficulty breathing, severe allergic reaction, loss of consciousness, or symptoms of overdose (blue/gray lips, slow breathing, gurgling sounds).